Antihypertensive drugs acting on the renin–angiotensin system (C09)
| ACE inhibitors ("-pril") |
|
|---|---|
| AIIRAs ("-sartan") | |
| Renin inhibitors ("-kiren") | |
| Dual ACE/NEP inhibitors |
|
| Neprilysin inhibitors | |
| |
| Combination of | |
|---|---|
| Telmisartan | Angiotensin II receptor antagonist |
| Amlodipine | Calcium channel blocker |
| Clinical data | |
| Trade names | Twynsta, others |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Telmisartan/amlodipine, sold under the brand name Twynsta among others, is a fixed-dose combination medication used to treat high blood pressure.[1] It is a combination of telmisartan, an angiotensin II receptor antagonist, and amlodipine, as the besilate, a calcium channel blocker.[1] It is taken by mouth.[1]
Common side effects include dizziness, swelling, and back pain.[1] Severe side effects may include low blood pressure, kidney problems, electrolyte problems, and a heart attack.[1] Use during pregnancy may harm the baby.[1] Telmisartan works by blocking the effects of angiotensin II while amlodipine works by decreasing calcium ion entry into smooth muscle and heart muscle.[1]
The combination was approved for medical use in the United States in 2009.[1] The combination is on the World Health Organization's List of Essential Medicines.[3][4] It is available as a generic medication.[5]
